Duke Study: Hospital Losses Incurred By CMS Payment For Drug-Eluting Stents
This article was originally published in The Gray Sheet
About two years will pass before inpatient costs associated with drug-eluting stents are accurately reflected in Medicare payment for the devices, causing hospital revenue loss in the short term, according to Kevin Schulman, MD, Duke Clinical Research Institute
You may also be interested in...
A provision that could be included in Medicare "giveback" legislation slated to be taken up by Congress this summer would allow drug-eluting stents to be assigned to a higher-paying diagnosis related group (DRG) midway through the fiscal year
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.